Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024
German Firm Commits To 2024 Biosimilars EBITDA Goal In Busy Q4 Call
Executive Summary
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.